(NASDAQ: PTCT) Ptc Therapeutics's forecast annual revenue growth rate of 18.37% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 32.79%, and while it is forecast to beat the US market's average forecast revenue growth rate of 13.21%.
Ptc Therapeutics's revenue in 2026 is $1,008,754,000.On average, 16 Wall Street analysts forecast PTCT's revenue for 2026 to be $107,414,052,174, with the lowest PTCT revenue forecast at $97,649,138,340, and the highest PTCT revenue forecast at $117,930,113,226. On average, 16 Wall Street analysts forecast PTCT's revenue for 2027 to be $119,849,711,672, with the lowest PTCT revenue forecast at $88,969,214,932, and the highest PTCT revenue forecast at $167,756,212,020.
In 2028, PTCT is forecast to generate $141,215,676,984 in revenue, with the lowest revenue forecast at $97,816,059,944 and the highest revenue forecast at $203,894,739,286.